These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 24193402)

  • 41. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
    Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
    Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions.
    Lin YT; Chang YC; Hui RC; Yang CH; Ho HC; Hung SI; Chung WH
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):356-64. PubMed ID: 22211830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential cytokine profiles produced by anti-epileptic drug re-exposure of peripheral blood mononuclear cells derived from severe anti-epileptic drug patients and non-allergic controls.
    Srinoulprasert Y; Kumkamthornkul P; Tuchinda P; Wongwiangjunt S; Sathornsumetee S; Jongjaroenprasert K; Kulthanan K
    Cytokine; 2022 Sep; 157():155951. PubMed ID: 35772364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
    Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
    Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
    Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
    Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea.
    Yang MS; Kim JY; Kang MG; Lee SY; Jung JW; Cho SH; Min KU; Kang HR
    Korean J Intern Med; 2019 Jan; 34(1):195-201. PubMed ID: 29466850
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
    Halevy S
    Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
    Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
    Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
    Sane SP; Bhatt AD
    J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
    Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
    Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.
    Kannenberg SM; Jordaan HF; Koegelenberg CF; Von Groote-Bidlingmaier F; Visser WI
    QJM; 2012 Sep; 105(9):839-46. PubMed ID: 22543685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.
    Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP
    Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis.
    Genin E; Chen DP; Hung SI; Sekula P; Schumacher M; Chang PY; Tsai SH; Wu TL; Bellón T; Tamouza R; Fortier C; Toubert A; Charron D; Hovnanian A; Wolkenstein P; Chung WH; Mockenhaupt M; Roujeau JC
    Pharmacogenomics J; 2014 Jun; 14(3):281-8. PubMed ID: 24322785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?
    Bouvresse S; Valeyrie-Allanore L; Ortonne N; Konstantinou MP; Kardaun SH; Bagot M; Wolkenstein P; Roujeau JC
    Orphanet J Rare Dis; 2012 Sep; 7():72. PubMed ID: 23009177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
    Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
    Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
    Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
    Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
    Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
    J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiepileptic Medication-induced Severe Cutaneous Adverse Reactions in Hospitalized Children: A Retrospective Study.
    Abtahi-Naeini B; Makhmali R; Amini N; Reza Maracy M; Nouri N; Momen T
    Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):139-148. PubMed ID: 38822509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
    Chung WH; Hung SI
    J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs.
    Lee SY; Nam YH; Koh YI; Kim SH; Kim S; Kang HR; Kim MH; Lee JG; Park JW; Park HK; La HO; Kim MY; Park SJ; Kwon YE; Jung JW; Kim SH; Kim CW; Yang MS; Kang MG; Lee JY; Kim JH; Kim SH; Hur GY; Jee YK; Jin HJ; Park CS; Jeong YY; Ye YM
    Allergy Asthma Immunol Res; 2019 Mar; 11(2):212-221. PubMed ID: 30661313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.